Based on the key indicators related to PTC Therapeutics' liquidity, profitability, solvency, and operating efficiency, PTC Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, PTC Therapeutics' Total Liabilities is comparatively stable compared to the past year. Property Plant Equipment is likely to gain to about 87.7 M in 2024, whereas Short Term Investments are likely to drop slightly above 281.6 M in 2024. Key indicators impacting PTC Therapeutics' financial strength include:
The essential information of the day-to-day investment outlook for PTC Therapeutics includes many different criteria found on its balance sheet. An individual investor should monitor PTC Therapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in PTC Therapeutics.
Net Income
(595.27 Million)
PTC
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Capital Expenditures
Total Cash From Financing Activities
Change To Liabilities
End Period Cash Flow
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Total Cash From Operating Activities
Change To Account Receivables
Net Income
Sale Purchase Of Stock
Change To Inventory
Investments
Change Receivables
Net Borrowings
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Other Cashflows From Investing Activities
Change To Netincome
Exchange Rate Changes
Change To Operating Activities
Issuance Of Capital Stock
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Other Liab
Accounts Payable
Cash
Other Assets
Long Term Debt
Short Term Investments
Other Current Assets
Total Liab
Preferred Stock Total Equity
Property Plant Equipment
Short Long Term Debt Total
Property Plant And Equipment Net
Current Deferred Revenue
Net Debt
Retained Earnings
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Net Receivables
Common Stock Total Equity
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Stockholder Equity
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Short Term Debt
Common Stock
Net Tangible Assets
Good Will
Retained Earnings Total Equity
Capital Surpluse
Inventory
Deferred Long Term Liab
Non Current Liabilities Other
Intangible Assets
Long Term Debt Total
Short Long Term Debt
Net Invested Capital
Net Working Capital
Capital Stock
Capital Lease Obligations
Interest Expense
Total Revenue
Research Development
Cost Of Revenue
Depreciation And Amortization
Selling General Administrative
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Net Income From Continuing Ops
Non Operating Income Net Other
Tax Provision
Interest Income
Net Interest Income
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past PTC Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of PTC Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in PTC Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in PTC Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of PTC Therapeutics. Check PTC Therapeutics' Beneish M Score to see the likelihood of PTC Therapeutics' management manipulating its earnings.
PTC Therapeutics Stock Summary
PTC Therapeutics competes with Krystal Biotech, Sarepta Therapeutics, Iovance Biotherapeutics, Madrigal Pharmaceuticals, and Blueprint Medicines. PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey. Ptc Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1167 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what PTC Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining PTC Therapeutics's current stock value. Our valuation model uses many indicators to compare PTC Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across PTC Therapeutics competition to find correlations between indicators driving PTC Therapeutics's intrinsic value. More Info.
PTC Therapeutics is rated below average in return on equity category among its peers. It is regarded third in return on asset category among its peers . At this time, PTC Therapeutics' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value PTC Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
PTC Therapeutics Systematic Risk
PTC Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. PTC Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on PTC Therapeutics correlated with the market. If Beta is less than 0 PTC Therapeutics generally moves in the opposite direction as compared to the market. If PTC Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one PTC Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of PTC Therapeutics is generally in the same direction as the market. If Beta > 1 PTC Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
PTC Therapeutics Thematic Clasifications
PTC Therapeutics is part of Cancer Fighters investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases
This theme covers Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases. Get More Thematic Ideas
Today, most investors in PTC Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various PTC Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of PTC Therapeutics growth as a starting point in their analysis.
PTC Therapeutics December 1, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of PTC Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of PTC Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of PTC Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing PTC Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build PTC Therapeutics's daily price indicators and compare them against related drivers.
When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.